Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMarin Pharmaceutical, a developer of biopharmaceuticals for serious diseases and medical conditions, is set to take over Pfizer's bulk biologics Shanbally, Cork, Ireland-based manufacturing plant for $48.5m.
Subscribe to our email newsletter
Following the acquisition, the plant will be licensed to produce N-acetylgalactosamine 6-sulfatase (GALNS) by 2015.
BioMarin CEO Jean-Jacques Bienaime said they believe that additional manufacturing capabilities beyond their current resources will be needed to support anticipated peak sales for GALNS, PEG-PAL for PKU, BMN 701 for Pompe disease, BMN 111 for achondroplasia, if they continue to progress to approval, and their other preclinical programs.
"The new facility is utilizing disposable technology and flexibly designed and will allow us to run either fed batch or perfusion processes," Bienaime said.
The transaction is expected to be closed in the third quarter of 2011.